tiprankstipranks
IO Biotech (IOBT)
NASDAQ:IOBT
US Market

IO Biotech (IOBT) Income Statement

160 Followers

IO Biotech Income Statement

Last quarter (Q4 2023), IO Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, IO Biotech's net income was $-26.18M. See IO Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 91.44M$ 91.44M$ 71.42M$ 41.23M$ 10.14M$ 9.91M
Operating Income
$ -91.44M$ -91.44M$ -71.42M$ -41.23M$ -10.14M$ -9.91M
Net Non Operating Interest Income Expense
$ 2.22M-$ -302.00K$ -26.90M$ -26.00K$ -6.00K
Other Income Expense
$ -3.66M$ -5.88M$ -1.41M-$ -1.87M$ -824.00K
Pretax Income
$ -85.23M$ -85.23M$ -70.19M$ -74.92M$ -12.04M$ -10.74M
Tax Provision
$ 852.00K$ 852.00K$ 1.27M$ 68.00K$ 0.00-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -86.08M$ -86.08M$ -71.46M$ -74.99M$ -14.59M$ -10.74M
Basic EPS
$ -2.15$ -1.98$ -2.48$ -17.30$ -2.49$ -2.22
Diluted EPS
$ -2.15$ -1.98$ -2.48$ -17.30$ -2.49$ -2.22
Basic Average Shares
$ 174.16M$ 43.54M$ 28.82M$ 4.34M$ 4.83M$ 4.83M
Diluted Average Shares
$ 174.16M$ 43.54M$ 28.82M$ 4.34M$ 4.83M$ 4.83M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 91.44M$ 91.44M$ 71.42M$ 41.23M$ 10.14M$ 9.91M
Net Income From Continuing And Discontinued Operation
$ -86.08M$ -86.08M$ -71.46M$ -74.99M$ -12.04M$ -10.74M
Normalized Income
$ -59.23M$ -67.33M--$ -12.16M$ -10.70M
Interest Expense
----$ 26.00K$ 6.00K
EBIT
$ -85.23M$ -85.23M$ -69.88M$ -74.56M$ -12.02M$ -10.74M
EBITDA
$ -84.47M$ -84.47M$ -69.34M$ -74.56M$ -12.02M$ -10.74M
Currency in USD

IO Biotech Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis